Business Combinations

12 Months Ended

Dec. 31, 2011

Business Combinations [Abstract]

Business Combinations

(4)  Business Combinations

(a)  Acquisitions in 2011

(i)  Arriva

On November 23, 2011, we acquired Arriva Medical LLC, or Arriva, located in Coral Springs, Florida, a privately-owned mail-order provider of home-diabetes testing products and supplies. The preliminary aggregate purchase price was $79.5 million, which consisted of a cash payment totaling $64.4 million and 806,452 shares of our common stock with an aggregate fair value of $15.2 million. Included in our consolidated statement of operations for the year ended December 31, 2011 is revenue totaling approximately $5.3 million related to this acquired business. The operating results of Arriva are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is deductible for tax purposes.

(ii)  Axis-Shield

On November 1, 2011, we acquired Axis-Shield, located in Dundee, Scotland, a U.K. publicly traded company focused on the development and manufacture of in vitro diagnostic tests for use in clinical laboratories and at the point of care. The preliminary aggregate purchase price was $388.8 million, which consisted of a cash payment totaling $274.4 million, fair value of previously-held investment totaling $109.2 million and an outstanding obligation to settle the remaining outstanding shares of $5.3 million. Included in our consolidated statement of operations for the year ended December 31, 2011 is revenue totaling approximately $36.7 million, including $1.8 million of license and royalty revenue, related to this acquired business. The operating results of Axis-Shield are included in our professional diagnostics reporting unit and business segment. We do not expect the amount allocated to goodwill to be deductible for tax purposes.

(iii)  Avee

On October 3, 2011, we acquired Avee Laboratories Inc. and related companies, which we refer to collectively as Avee, located in Tampa, Florida, a privately-owned provider of drug testing services in the field of pain management. The aggregate purchase price was $120.5 million, which was paid in cash. Included in our consolidated statement of operations for the year ended December 31, 2011 is revenue totaling approximately $27.2 million related to this acquired business. The operating results of Avee are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is deductible for tax purposes.

(iv)  Other acquisitions in 2011

During 2011, we acquired the following businesses for a preliminary aggregate purchase price of $198.4 million, which included cash payments totaling $139.2 million, 25,463 shares of our common stock with an acquisition date fair value of $1.0 million, contingent consideration obligations with an aggregate acquisition date fair value of $48.7 million and deferred purchase price consideration of $4.2 million.

• 90% interest in BioNote, Inc., or BioNote, headquartered in South Korea, a manufacturer of diagnostic products for the veterinary industry (Acquired January 2011). We previously owned a 10% interest in BioNote.

• assets, including domain name, of Pregnancy.org, LLC, or Pregnancy.org, a U.S.-based company providing a website for preconception, pregnancy and newborn care content, tools and sharing (Acquired January 2011)

• Home Telehealth Limited, subsequently renamed Alere Connected Health Limited, or Alere Connected Health, located in Cardiff, Wales, a company that focuses on delivering integrated, comprehensive services and programs to health and social care providers and insurers (Acquired February 2011)

• Bioeasy Diagnostica Ltda., or Bioeasy, located in Belo Horizonte, Brazil, a company that markets and sells rapid diagnostic tests and systems for laboratory diagnosis, prevention and monitoring of immunological diseases and fertility (Acquired March 2011)

• 80.92% interest in Standing Stone, Inc., or Standing Stone, located in Westport, Connecticut, a company that focuses on disease state management by enhancing the quality of care provided to patients who require long-term therapy for chronic disease management (Acquired May 2011)

• certain assets, rights, liabilities and properties of Drug Detection Devices, Inc., or 3DL, located in Alpharetta, Georgia, a distributor that promotes, markets, distributes and sells drugs of abuse diagnostic products, including consumables, point-of-care diagnostic kits and related products and services (Acquired July 2011)

• Colibri Medical AB, or Colibri, located in Helsingborg, Sweden, a distributor of point-of-care drugs of abuse diagnostic products primarily to the Scandinavian marketplace (Acquired July 2011)

• Laboratory Data Systems, Inc., or LDS, located in Tampa, Florida, a provider of healthcare software products, services, consulting and solutions (Acquired August 2011)

• certain assets, liabilities and properties of Abatek Medical LLC, or Abatek, located in Dover, New Hampshire, a distributor that promotes, markets, distributes and sells drugs of abuse diagnostic products, including consumables, point-of-care diagnostic kits and related products and services (Acquired September 2011)

• Forensics Limited, or ROAR, located in Worcestershire, England, a company that provides forensic quality toxicology services across the United Kingdom (Acquired September 2011)

• Mahsan Diagnostika Vertriebsgesellschaft mbH, or Mahsan, located in Reinbek, Germany, a distributor of in vitro diagnostic drugs of abuse products primarily to the German marketplace (Acquired October 2011)

• Medical Automation Systems Inc., or MAS, located in Charlottesville, Virginia, a provider of network-based software solutions for point-of-care testing (Acquired October 2011)

• certain assets and properties of 1 Medical Distribution, Inc., or 1 Medical, located in Worthington, Ohio, a distributor that promotes, markets, distributes and sells drugs of abuse diagnostic products, including consumables, point-of-care diagnostic kits and related products and services (Acquired November 2011)

• Method Factory, Inc. (d/b/a Wellogic), or Wellogic, headquartered in Waltham, Massachusetts, a provider of software solutions designed to connect the healthcare community (Acquired December 2011)

The operating results of BioNote, Bioeasy, 3DL, Colibri, LDS, Abatek, ROAR, Mahsan, MAS and 1 Medical are included in our professional diagnostics reporting unit and business segment. The operating results of Pregnancy.org, Alere Connected Health, Standing Stone and Wellogic are included in our health management reporting unit and business segment.

Our consolidated statement of operations for the year ended December 31, 2011 included revenue totaling approximately $21.1 million related to these businesses. Goodwill has been recognized in all of the acquisitions, with the exception of 1 Medical, and amounted to approximately $135.8 million. Goodwill related to the acquisitions of Pregnancy.org, 3DL, Abatek, LDS and Wellogic, which totaled $32.4 million, is expected to be deductible for tax purposes. The goodwill related to the remaining 2011 acquisitions is not expected to be deductible for tax purposes.

A summary of the preliminary aggregate purchase price allocation for the acquisitions consummated in 2011 is as follows (in thousands):

	Avee		Arriva		Axis-Shield		Other		Total
Current assets(1)	$	9,811	$	8,366	$	92,813	$	24,688	$	135,678
Property, plant and equipment		5,411		524		50,718		11,820		68,473
Goodwill		30,038		55,827		143,188		135,828		364,881
Intangible assets		76,400		27,400		224,921		79,454		408,175
Other non-current assets		—		35		19,833		6,290		26,158
Total assets acquired		121,660		92,152		531,473		258,080		1,003,365
Current liabilities		1,170		12,613		47,024		27,603		88,410
Non-current liabilities		—		—		95,600		32,008		127,608
Total liabilities assumed		1,170		12,613		142,624		59,611		216,018
Net assets acquired		120,490		79,539		388,849		198,469		787,347
Less:
Contingent consideration		—		—		—		48,685		48,685
Fair value of previously-held equity investment		—		—		109,231		3,937		113,168
Obligation to purchase outstanding shares		—		—		5,264		—		5,264
Fair value of common stock issued		—		15,183		—		1,000		16,183
Loan forgiveness		—		—		—		1,489		1,489
Deferred purchase price consideration		—		—		—		4,170		4,170
Cash paid	$	120,490	$	64,356	$	274,354	$	139,188	$	598,388

(1) Includes cash acquired of approximately $23.2 million.

The following are the intangible assets acquired and their respective amortizable lives (dollars in thousands):

	Avee		Arriva		Axis-Shield		Other		Total		Weighted- average Useful Life
Core technology and patents	$	—	$	—	$	55,580	$	19,740	$	75,320	10.1 years
Database		—		—		—		64		64	3.0 years
Trademarks and trade names		1,700		1,000		4,145		7,352		14,197	10.1 years
Customer relationships		71,500		23,000		108,052		35,051		237,603	11.9 years
Non-compete agreements		3,200		3,400		—		1,706		8,306	5.3 years
Software		—		—		—		7,400		7,400	10.9 years
Other		—		—		—		7,767		7,767	15.6 years
In-process research and development		—		—		57,144		374		57,518	N/A
Total intangible assets	$	76,400	$	27,400	$	224,921	$	79,454	$	408,175

(b)  Acquisitions in 2010

(i)  Immunalysis

On August 16, 2010, we acquired Diagnostixx of California, Corp. (d/b/a Immunalysis Corporation), or Immunalysis, located in Pomona, California, a privately-owned manufacturer and marketer of abused and prescription drug screening solutions used by clinical reference and forensic/crime laboratories. The aggregate purchase price was $56.2 million, which consisted of an initial cash payment totaling $55.0 million and a contingent consideration obligation of up to $5.0 million with an acquisition date fair value of $1.2 million. Included in our consolidated statement of operations for the year ended December 31, 2010 is revenue totaling approximately $7.9 million related to this acquired business. The operating results of this acquired operation are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is deductible for tax purposes.

(ii)  Twist

On March 11, 2010, we acquired TwistDx, Inc., or Twist, headquartered in Cambridge, Massachusetts, a privately-owned research and development company with a research and development operation in the United Kingdom. The aggregate purchase price was $70.8 million, which consisted of an initial cash payment totaling $35.2 million and a contingent consideration obligation of up to $125.0 million with an acquisition date fair value of $35.6 million. Included in our consolidated statement of operations for the year ended December 31, 2010 is revenue totaling approximately $0.2 million related to this acquired business. The operating results of this acquired operation are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is not deductible for tax purposes.

(iii)  Alere Toxicology

On February 17, 2010, we acquired Kroll Laboratory Specialists, Inc., subsequently renamed Alere Toxicology Services, or Alere Toxicology, headquartered in Gretna, Louisiana, which provides forensic quality substance abuse testing products and services across the United States. The aggregate purchase price was $109.5 million, which was paid in cash. Included in our consolidated statement of operations for the year ended December 31, 2010 is revenue totaling approximately $31.3 million related to this acquired business. The operating results of Alere Toxicology are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is deductible for tax purposes.

(iv)  Standard Diagnostics

On February 8, 2010, we acquired a 61.92% ownership interest in Standard Diagnostics via a tender offer for approximately $162.1 million. On March 22, 2010, we acquired an incremental 13.37% ownership interest in Standard Diagnostics via a follow-on tender offer for approximately $36.2 million. In June 2010, we acquired an incremental 2.84% ownership interest for approximately $7.3 million, bringing our acquisition-related aggregate ownership interest in Standard Diagnostics to approximately 78.13%. Standard Diagnostics specializes in the medical diagnostics industry. Its main product lines relate to diagnostic reagents and devices for hepatitis, infectious diseases, tumor markers, fertility, drugs of abuse, urine strips and protein strips. The aggregate purchase price was $205.6 million in cash. Included in our consolidated statement of operations for the year ended December 31, 2010 is revenue totaling approximately $78.9 million related to Standard Diagnostics. The operating results of Standard Diagnostics are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is not deductible for tax purposes. During the fourth quarter of 2010, we acquired the remaining outstanding minority interests in Standard Diagnostics bringing our aggregate ownership interest to approximately 100% as of December 31, 2010. In connection with our purchase of shares from a certain minority shareholder, we incurred a compensation charge of $60.1 million, as a result of the transition of the day-to-day management control of the business to us.

(v)  Other acquisitions in 2010

During 2010, we acquired the following businesses for an aggregate purchase price of $161.9 million, which consisted of initial cash payments totaling $108.3 million, contingent consideration obligations with an acquisition date fair value of $52.9 million and deferred purchase price consideration with an acquisition date present value of $0.7 million.

• RMD Networks, Inc., or RMD, located in Denver, Colorado, a provider of clinical groupware software and services designed to improve communication and coordination of care among providers, patients, and payers in the healthcare environment (Acquired January 2010)

• certain assets of Streck, Inc., or Streck, located in Nebraska, a manufacturer of hematology, chemistry and immunology products for the clinical laboratory (Acquired January 2010)

• assets of the diagnostics division of Micropharm Ltd., or Micropharm, located in Wales, United Kingdom, an expert in high quality antibody production in sheep for both diagnostic and therapeutic purposes, providing antisera on a contract basis for U.K. and overseas companies and academic institutions, mainly for research, therapeutic and diagnostic uses (Acquired March 2010)

• Quantum Diagnostics Group Limited, or Quantum, headquartered in Essex, England, an independent provider of drug testing products and services to healthcare professionals across the U.K. and Europe (Acquired April 2010)

• assets of the workplace health division of Good Health Solutions Pty Ltd., subsequently renamed Alere Health Pty Ltd., located in East Sydney, Australia, an important player in the Australian health and wellness market, focusing on health screenings, health related consulting services, health coaching and fitness instruction (Acquired April 2010)

• certain assets of Unotech Diagnostics, Inc., or Unotech, located in California, a privately-owned company engaged in the development, formulation, manufacture, packaging, supply and distribution of our BladderCheck NMP22 lateral flow test and related lateral flow products (Acquired June 2010)

• Scipac Holdings Limited, or Scipac, headquartered in Kent, England, a diagnostic reagent company with an extensive product portfolio supplying purified human antigens, recombinant proteins and disease state plasma to a global customer base (Acquired June 2010)

• Ionian Technologies, Inc., or Ionian, located in San Diego, California (Acquired July 2010)

• AdnaGen AG, now known as AdnaGen GmbH, or AdnaGen, located in Langenhagen, Germany, a company that focuses on the development of innovative tumor diagnostics for the detection of rare cells (Acquired November 2010)

• Medlab Produtos Medicos Hospitalares Ltda, now known as Alere S.A., located in San Paulo, Brazil, a distributor of medical instruments and reagents to public and private laboratories throughout Brazil and Uruguay (Acquired December 2010)

• Capital Toxicology, LLC, or Capital Toxicology, located in Austin, Texas, a privately-held toxicology business specializing in pain management services (Acquired December 2010)

The operating results of the acquired businesses mentioned above, except for RMD and Alere Health Pty Ltd., are included in our professional diagnostics reporting unit and business segment. The operating results of RMD and Alere Health Pty Ltd. are included in our health management reporting unit and business segment. Our consolidated statement of operations for the year ended December 31, 2010 included revenue totaling approximately $12.6 million related to these businesses. Goodwill has been recognized in all of the acquisitions, with the exception of Unotech and Micropharm, and amounted to approximately $116.2 million. Goodwill related to the acquisition of Capital Toxicology, which totaled $11.6 million, is deductible for tax purposes. Goodwill related to all other acquisitions is not deductible for tax purposes.

A summary of the aggregate purchase price allocation for the acquisitions consummated in 2010 is as follows (in thousands):

	Immunalysis		Twist		Alere Toxicology		Standard Diagnostics		Other		Total
Current assets(1)	$	6,933	$	373	$	6,044	$	51,056	$	20,829	$	85,235
Property, plant and equipment		1,076		152		3,300		18,580		13,149		36,257
Goodwill		18,234		61,463		53,435		33,798		116,186		283,116
Intangible assets		30,600		15,700		48,400		131,179		57,976		283,855
Other non-current assets		—		—		—		16,426		562		16,988
Total assets acquired		56,843		77,688		111,179		251,039		208,702		705,451
Current liabilities		569		731		1,640		13,389		14,749		31,078
Non-current liabilities		50		6,107		—		32,088		32,024		70,269
Total liabilities assumed		619		6,838		1,640		45,477		46,773		101,347
Net assets acquired		56,224		70,850		109,539		205,562		161,929		604,104
Less:
Contingent consideration		1,200		35,600		—		—		52,908		89,708
Present value of deferred purchase price consideration		—		—		—		—		688		688
Cash paid	$	55,024	$	35,250	$	109,539	$	205,562	$	108,333	$	513,708

(1) Includes cash acquired of approximately $22.9 million.

The following are the intangible assets acquired and their respective amortizable lives (dollars in thousands):

	Immunalysis		Twist		Alere Toxicology		Standard Diagnostics		Other		Total		Weighted- average Useful Life
Core technology and patents	$	8,800	$	8,600	$	13,300	$	62,135	$	14,050	$	106,885	12.4 years
Quality systems		—		—		—		—		153		153	5 years
Database		—		—		—		—		654		654	3 years
Trademarks and trade names		800		—		—		9,350		1,504		11,654	6.3 years
License agreements		—		—		—		—		459		459	5 years
Customer relationships		19,900		—		35,100		45,754		24,578		125,332	14.3 years
Non-compete agreements		300		—		—		255		2,095		2,650	4.2 years
Software		—		—		—		—		5,000		5,000	7 years
Distribution agreement		800		—		—		—		—		800	14 years
Manufacturing know-how		—		—		—		—		3,683		3,683	10.5 years
In-process research and development		—		7,100		—		13,685		5,800		26,585	N/A
Total intangible assets	$	30,600	$	15,700	$	48,400	$	131,179	$	57,976	$	283,855

(c)  Acquisitions in 2009

(i)  Acquisition of Tapestry Medical

On November 6, 2009, we acquired Tapestry Medical, Inc., now known as Alere Home Monitoring, Inc., or Alere Home Monitoring, located in Livermore, California, a privately-owned company that is a provider of products and related services designed to support anti-coagulation disease management for patients at risk for stroke and other clotting disorders. The aggregate purchase price was $58.7 million, which consisted of cash payments totaling $42.7 million and a contingent consideration obligation with a fair value of $16.0 million payable in shares of our common stock, except in the case of the 2010 earn-out which will be paid in cash. Included in our consolidated statements of operations for the year ended December 31, 2009 is revenue totaling approximately $1.8 million related to Alere Home Monitoring. The operating results of Alere Home Monitoring are included in our health management reporting unit and business segment. The amount allocated to goodwill from this acquisition is deductible for tax purposes.

(ii)  Acquisition of Free & Clear

On September 28, 2009, we acquired Free & Clear, Inc., now known as Alere Wellbeing, Inc., or Alere Wellbeing, located in Seattle, Washington, a privately-owned company that specializes in behavioral coaching to help employers, health plans and government agencies improve the overall health and productivity of their covered populations. The aggregate purchase price was $121.5 million, which consisted of an initial cash payment totaling $107.3 million and a contingent consideration obligation with a fair value of $14.2 million. Included in our consolidated statements of operations for the year ended December 31, 2009 is revenue totaling approximately $14.3 million related to Alere Wellbeing. The operating results of Alere Wellbeing are included in our health management reporting unit and business segment. The amount allocated to goodwill from this acquisition is not deductible for tax purposes.

(iii)  Acquisition of Concateno

On August 11, 2009, we acquired Concateno plc, or Concateno, a publicly-traded company headquartered in the United Kingdom that specializes in the manufacture and distribution of rapid drugs of abuse diagnostic products used in health care, criminal justice, workplace and other testing markets. The aggregate purchase price was $251.9 million, which consisted of $178.8 million in cash, including $0.5 million of cash paid for shares of Concateno common stock which we acquired prior to the acquisition date, 2,091,080 shares of our common stock with an aggregate fair value of $70.2 million and $2.9 million of fair value associated with Concateno employee stock options exchanged as part of the transaction. Our consolidated statements of operations for the year ended December 31, 2009 included revenue totaling approximately $33.3 million related to Concateno. The operating results of Concateno are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is not deductible for tax purposes.

(iv)  Acquisition of ACON’s Second Territory Business

On April 30, 2009, we completed our acquisition of the assets of ACON Laboratories, Inc.’s and certain related entities’ (collectively, “ACON”) business of researching, developing, manufacturing, distributing, marketing and selling lateral flow immunoassay and directly-related products (the “Business”) for the remainder of the world outside of the First Territory (as defined below), including China, Asia Pacific, Latin America, South America, the Middle East, Africa, India, Pakistan, Russia and Eastern Europe (the “Second Territory Business”). We acquired ACON’s Business in the United States, Canada, Western Europe (excluding Russia, the former Soviet Republics that are not part of the European Union and Turkey), Israel, Australia, Japan and New Zealand (the “First Territory”) in March 2006. The aggregate purchase price for the Second Territory Business was approximately $191.0 million ($188.9 million present value), which consisted of cash payments totaling $104.7 million, 1,202,691 shares of our common stock with an aggregate fair value of $42.1 million and deferred purchase price consideration payable in cash and common stock with an aggregate fair value of $42.1 million. Our consolidated statements of operations for the year ended December 31, 2009 included revenue totaling approximately $38.0 million related to the Second Territory Business. The operating results of the Second Territory Business are included in our professional diagnostics reporting unit and business segment. Goodwill resulting from this acquisition is generally not expected to be deductible for tax purposes depending on the tax jurisdiction.

(v)  Other acquisitions in 2009

During 2009, we acquired the following assets and businesses for an aggregate purchase price of $85.8 million ($83.9 million present value), which consisted of $45.4 million in cash, 128,513 shares of our common stock with an aggregate fair value of $5.1 million, notes payable totaling $7.9 million, deferred purchase price consideration payable in cash with an aggregate fair value of $15.8 million, warrants with a fair value of $0.1 million and contingent consideration obligations with an aggregate fair value of $9.6 million, which is recorded as a liability, of which $5.4 million is payable in shares of our common stock.

• GeneCare Medical Genetics Center, Inc., or GeneCare, located in Chapel Hill, North Carolina, a medical genetics testing and counseling business (Acquired July 2009)

• Certain assets from CVS Caremark’s Accordant Common disease management programs, or Accordant, whereby chronically-ill patients served by Accordant Common disease management programs will be managed and have access to expanded offerings provided by Alere (Acquired August 2009)

• ZyCare, Inc., or ZyCare, located in Chapel Hill, North Carolina, a provider of technology and services used to help manage many chronic illnesses (Acquired August 2009)

• Medim Schweiz GmbH., now known as Alere GmbH, located in Zug, Switzerland, a distributor of point-of-care diagnostics testing products primarily to the Swiss marketplace (Acquired September 2009)

• Biosyn Diagnostics Limited, now known as Alere Health Limited, located in Belfast, Ireland, a distributor of point-of-care diagnostics testing products primarily to the Irish marketplace (Acquired October 2009)

• Mologic Limited, or Mologic, located in Sharnbrook, United Kingdom, a research and development entity having extensive experience in applied immunoassay technology, as well as a broad understanding of medical diagnostic devices and antibody development (Acquired October 2009)

• Jinsung Meditech, Inc., now known as Alere Healthcare Inc., or Alere Healthcare, located in Seoul, South Korea, a distributor of point-of-care diagnostics testing products primarily to the South Korean marketplace (Acquired December 2009)

• Biolinker S.A., or Biolinker, located in Buenos Aires, Argentina, a distributor of point-of-care diagnostics testing products primarily to the Argentinean marketplace (Acquired December 2009)

• 51.0% share in Long Chain International Corp., located in Taipei, Taiwan, a distributor of point-of-care diagnostics testing products primarily to the Taiwanese marketplace (Acquired December 2009). In January 2010, we acquired the remaining 49.0% interest in Long Chain International Corp., now known as Alere Health Corporation.

The operating results of Alere GmbH, Alere Health Limited, Mologic, Alere Healthcare, Biolinker and Alere Health Corporation are included in our professional diagnostics reporting unit and business segment. The operating results of GeneCare, Accordant and Zycare are included in our health management reporting unit and business segment. Our consolidated statements of operations for the year ended December 31, 2009 included revenue totaling approximately $19.6 million related to these businesses. Goodwill has been recognized in all transactions and amounted to approximately $35.6 million. Goodwill related to the acquisitions of GeneCare and Accordant, which totaled $12.8 million, is deductible for tax purposes. Goodwill related to all other acquisitions is not deductible for tax purposes.

A summary of the aggregate purchase price allocation for the acquisitions consummated in 2009 is as follows (in thousands):

	Alere Home Monitoring		Alere Wellbeing		Concateno		Second Territory Business		Other		Total
Current assets(1)	$	2,682	$	18,723	$	38,292	$	4,156	$	23,130	$	86,983
Property, plant and equipment		5,026		1,224		5,192		305		1,272		13,019
Goodwill		42,732		80,293		156,563		83,976		35,563		399,127
Intangible assets		10,680		44,100		102,735		100,600		40,861		298,976
Other non-current assets		25		1,786		2,405		—		631		4,847
Total assets acquired		61,145		146,126		305,187		189,037		101,457		802,952
Current liabilities		2,413		6,948		20,589		117		11,027		41,094
Non-current liabilities		13		17,640		32,707		—		6,531		56,891
Total liabilities assumed		2,426		24,588		53,296		117		17,558		97,985
Net assets acquired		58,719		121,538		251,891		188,920		83,899		704,967
Less:
Contingent consideration		16,000		14,208		—		—		9,606		39,814
Notes payable		—		—		—		—		7,912		7,912
Fair value of common stock issued and options exchanged		—		—		73,099		42,142		5,172		120,413
Present value of deferred purchase price consideration		—		—		—		42,089		15,764		57,853
Cash paid	$	42,719	$	107,330	$	178,792	$	104,689	$	45,445	$	478,975

(1) Includes cash acquired of approximately $18.4 million.

The following are the intangible assets acquired and their respective amortizable lives (dollars in thousands):

	Alere Home Monitoring		Alere Wellbeing		Concateno		Second Territory Business		Other		Total		Weighted- average Useful Life
Core technology and patents	$	—	$	4,600	$	500	$	3,000	$	5,220	$	13,320	6.5 years
Supply arrangements		—		—		—		—		1,581		1,581	8 years
Trademarks and trade names		3,000		3,400		25,184		1,900		270		33,754	14.1 years
Customer relationships		6,500		36,100		77,051		94,200		31,074		244,925	14.9 years
Non-compete agreements		1,180		—		—		1,500		1,600		4,280	2.9 years
In-process research and development		—		—		—		—		1,116		1,116	N/A
Total intangible assets	$	10,680	$	44,100	$	102,735	$	100,600	$	40,861	$	298,976

(d)  Restructuring Plans Related to Business Combinations

In connection with several of our acquisitions consummated during 2008 and prior, we initiated integration plans to consolidate and restructure certain functions and operations, including the relocation and termination of certain personnel of these acquired entities and the closure of certain of the acquired entities’ leased facilities. These costs have been recognized as liabilities assumed in connection with the acquisition of these entities and are subject to potential adjustments as certain exit activities are confirmed or refined. Of the total $1.8 million liability outstanding as of December 31, 2011, $0.6 million is included in accrued expenses and other current liabilities and $1.2 million is included in other long-term liabilities.

(i)  Matria Acquisition

In connection with our acquisition of Matria in 2008, we implemented an integration plan to improve operating efficiencies and eliminate redundant costs resulting from the acquisition. The restructuring plan impacted all cost centers within the Matria organization, as activities were combined with our existing business operations. The following table summarizes the liabilities established for exit activities related to this acquisition (in thousands):

	Severance Related			Facility And Other			Total Exit Activities
Balance at December 31, 2008	$	3,952		$	—		$	3,952
Restructuring plan accruals and adjustments		158			4,815			4,973
Payments		(1,190	)		(1,924	)		(3,114	)
Balance at December 31, 2009		2,920			2,891			5,811
Restructuring plan accruals and adjustments		(1,536	)		(141	)		(1,677	)
Payments		(1,130	)		(1,783	)		(2,913	)
Balance at December 31, 2010		254			967			1,221
Restructuring plan accruals and adjustments		(176	)		—			(176	)
Payments		(10	)		(572	)		(582	)
Balance at December 31, 2011	$	68		$	395		$	463
Costs since inception	$	13,664		$	4,674		$	18,338

Although we believe our plan and estimated exit costs are reasonable, actual spending for exit activities may differ from current estimated exit costs.

(ii)  Cholestech Acquisition

During 2007, we formulated restructuring plans in connection with our acquisition of Cholestech Corporation, or Cholestech, consistent with our acquisition strategy to realize operating efficiencies and cost savings. Additionally, in March 2008, we announced plans to close the Cholestech facility in Hayward, California. We have transitioned the manufacturing of the related products to our facility in San Diego, California and have transitioned the sales and distribution of the products to our shared services center in Orlando, Florida. The following table summarizes the liabilities established for exit activities related to this acquisition (in thousands):

	Severance Related			Facility And Other			Total Exit Activities
Balance at December 31, 2008	$	3,946		$	2,732		$	6,678
Restructuring plan accruals and adjustments		49			—			49
Payments		(1,554	)		(12	)		(1,566	)
Balance at December 31, 2009		2,441			2,720			5,161
Restructuring plan accruals and adjustments		(631	)		—			(631	)
Payments		(1,725	)		(914	)		(2,639	)
Balance at December 31, 2010		85			1,806			1,891
Restructuring plan accruals and adjustments		(85	)		—			(85	)
Payments		—			(502	)		(502	)
Balance at December 31, 2011	$	—		$	1,304		$	1,304
Costs since inception	$	5,845		$	2,732		$	8,577

Although we believe our plan and estimated exit costs are reasonable, actual spending for exit activities may differ from current estimated exit costs. See Note 20 for additional restructuring charges related to the Cholestech facility closures and integrations.

(iii)  Other Acquisitions

In conjunction with our acquisitions of Panbio Limited, or Panbio, Biosite Incorporated, or Biosite, HemoSense, Inc., or HemoSense, Alere Medical, Inc., or Alere Medical, ParadigmHealth, Inc., or ParadigmHealth, Matritech, Inc., or Matritech, and Ostex we implemented integration plans to improve efficiencies and eliminate redundant costs resulting from the acquisitions. The following table summarizes the liabilities established for exit activities related to these acquisitions (in thousands):

	Severance Related			Facility And Other			Total Exit Activities
Balance at December 31, 2008	$	2,450		$	2,194		$	4,644
Restructuring plan accruals and adjustments		(4	)		502			498
Payments		(2,438	)		(1,307	)		(3,745	)
Currency adjustments		—			2			2
Balance at December 31, 2009		8			1,391			1,399
Restructuring plan accruals and adjustments		—			(140	)		(140	)
Payments		(8	)		(1,004	)		(1,012	)
Balance at December 31, 2010		—			247			247
Restructuring plan accruals and adjustments		—			(75	)		(75	)
Payments		—			(172	)		(172	)
Balance at December 31, 2011	$	—		$	—		$	—
Costs since inception	$	20,366		$	5,062		$	25,428

(e)  Pro Forma Financial Information

The following table presents selected unaudited financial information, including Standard Diagnostics, as if the acquisition of this entity had occurred on January 1, 2010. Pro forma results exclude adjustments for various other less significant acquisitions completed during 2010 and 2011, as these acquisitions did not materially affect our results of operations.

The pro forma results are derived from the historical financial results of the acquired business for the period presented and are not necessarily indicative of the results that would have occurred had the acquisition been consummated on January 1, 2010. There was no pro forma impact on the results of operations for 2011, as the acquisition of Standard Diagnostics closed prior to January 1, 2011 (in thousands, except per share amount).

	2010
Pro forma net revenue	$	2,161,500
Pro forma net loss from continuing operations attributable to Alere Inc. and Subsidiaries	$	(1,051,259	)
Pro forma net loss available to common stockholders	$	(1,041,545	)
Pro forma net loss from continuing operations attributable to Alere Inc. and Subsidiaries per common share — basic and diluted(1)	$	(12.45	)
Pro forma net loss available to common stockholders — basic and diluted(1)	$	(12.31	)

(1) Net loss per common share amounts are computed as described in Note 12.